Selank Peptide Research: Benefits, Studies, and Evidence

Selank is a synthetic heptapeptide researched for its relationship with anxiety biology, GABAergic signaling, and neurotrophic and immune modulation. An analog of the naturally occurring immunoregulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail, it emerged from the same Russian peptide-pharmacology program as Semax — and shares that program’s distinctive literature profile: deep, decades-long, and published overwhelmingly in Russian-language journals.

Selank’s split identity mirrors Semax’s. It is registered as an anxiolytic medicine in Russia, where it has been studied clinically for anxiety and neurasthenia — and an unapproved research compound everywhere else, including the United States. That geography defines everything about the evidence: real human data exists, but almost none of it was produced to international trial standards.

What Is Selank?

Selank is a chain of seven amino acids — Thr-Lys-Pro-Arg-Pro-Gly-Pro — built on the tuftsin sequence (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide appended to the C-terminus.

Tuftsin is a naturally occurring tetrapeptide derived from the Fc portion of immunoglobulin G, known for immunoregulatory and phagocytosis-stimulating activity. The Selank design, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences under S.B. Seredenin and N.F. Myasoedov, was an attempt to build an anxiolytic peptide around that tuftsin core: the Pro-Gly-Pro extension was added for stability against enzymatic degradation, and the resulting molecule was studied for selective anxiolytic effects without the sedation and muscle-relaxant side effects typical of benzodiazepines — a profile reported in the early Russian animal literature.

In Russia, Selank is registered as a prescription anxiolytic and has been studied clinically for generalized anxiety disorder and neurasthenia. It is not FDA approved and is not a registered medicine outside Russia and neighboring states.

Research has investigated Selank for its relationship with GABAergic neurotransmission, the enkephalin (endogenous opioid) system, BDNF expression, stress-response biology, and immune modulation.

How Does Selank Work?

Unlike benzodiazepines, Selank has been studied as a multi-pathway modulator rather than a direct receptor agonist. Researchers have investigated its relationship with:

• GABAergic neurotransmission — one of the clearest mechanistic findings: a 2016 open-access study reported that Selank administration altered expression of genes involved in GABAergic neurotransmission in rat brain, and related work examined how Selank influences GABA-receptor ligand binding — a finding that anchors Selank’s anxiolytic rationale
• The enkephalin system — animal research reported that Selank inhibited enkephalin-degrading enzymes, increasing the half-life of the endogenous opioid peptide leu-enkephalin in plasma. The anxiolytic effect observed in stressed mouse strains was proposed to be linked to this mechanism, positioning Selank partly within endogenous-opioid biology rather than only within classical neurotransmitter pharmacology
• BDNF expression — researchers have reported that intranasal Selank administration regulates BDNF expression at both the mRNA and protein levels in the rat hippocampus, connecting the peptide to the same neurotrophic-signaling biology studied with Semax — though the Selank BDNF literature is smaller
• Immune modulation — consistent with its tuftsin ancestry, Selank has been investigated for immunomodulatory effects, including in patients with anxiety-asthenic disorders, where researchers reported effects on immune parameters alongside the compound’s studied anxiolytic activity

Key Takeaway: Selank is particularly interesting to researchers because its studied profile — anxiolytic activity reported without the sedation associated with benzodiazepines — is investigated through indirect mechanisms (GABAergic gene modulation, enkephalin stabilization, BDNF expression) rather than through direct receptor agonism — though nearly all of this evidence comes from Russian-language preclinical literature.

Potential Benefits of Selank

Anxiety & Stress Research

Anxiolytic activity is Selank’s primary research context — and the basis of its registered use in Russia.

The most cited human study, published in 2008, compared Selank with the benzodiazepine medazepam in patients with generalized anxiety disorder and neurasthenia. The researchers reported comparable anxiolytic efficacy between the groups, with Selank additionally showing antiasthenic (anti-fatigue/weakness) and psychostimulant properties not observed with the benzodiazepine — and reported increases in the half-life (tau 1/2) of leu-enkephalin that correlated with anxiety reduction. A 2014 study compared Selank with phenazepam in anxiety-disorder patients and reported comparable anxiolytic effects with a favorable tolerability profile for Selank.

Animal research investigated Selank across standard anxiety paradigms — elevated plus-maze, open-field, and unpredictable chronic mild stress models — consistently reporting anxiolytic-like effects, including in combination with diazepam in stress-exposed rats.

The caveat: these human studies were conducted within Russia’s domestic clinical framework, with small samples and designs that differ from multinational trial standards.

Cognition & Memory Research

A secondary research thread investigated Selank in models of learning, memory, and stress-related cognitive impairment.

Animal studies reported that Selank exerted antiamnestic (memory-protective) effects, including in monkey models of cognitive disruption and in rat models of catecholamine-system damage during early development. The proposed link is the BDNF work: by upregulating hippocampal BDNF expression, Selank was hypothesized to support the neurotrophic biology underlying memory processes.

It is worth distinguishing these animal cognition findings, which are documented but narrow, from broader claims about nootropic enhancement that extend well beyond the evidence.

Immune & Inflammatory Research

True to its tuftsin origin, Selank has been investigated as an immunomodulatory peptide.

Researchers reported immunomodulatory effects of Selank in patients with anxiety-asthenic disorders, and experimental work examined its activity in models of viral infection. This line of research treats Selank less as a pure neuroactive compound and more as a bidirectional regulator of the neuroimmune interface — consistent with the broader Russian research tradition viewing stress, anxiety, and immunity as linked systems.

Selank vs. Other Peptides

Semax is Selank’s closest relative — another Russian-developed heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro vs. Met-Glu-His-Phe-Pro-Gly-Pro) from the same institutional program, with the same Pro-Gly-Pro stability tail. But their research focuses diverge: Semax is studied mainly for neurotrophic signaling and neuroprotection (BDNF/trkB, ischemia models), while Selank is studied mainly for anxiolytic and immunomodulatory biology. Researchers often pair them because they share a design philosophy — pituitary- and immune-derived peptide fragments repurposed as central-nervous-system probes.

Noopept (a Russian dipeptide nootropic) is sometimes discussed alongside Selank because both have been studied for BDNF expression in rat hippocampus — but Noopept is a distinct molecule (N-phenylacetyl-L-prolylglycine ethyl ester) with its own literature, and the two should not be confused.

Selank’s research is more closely associated with:

Tuftsin-Derived Heptapeptide → GABAergic Gene Modulation + Enkephalin Stabilization → Anxiolytic & Immunomodulatory Biology

What sets Selank apart is the claim the early Russian literature made for it: an anxiolytic peptide without benzodiazepine-style sedation — a profile supported by the domestic clinical comparisons but never tested in international trials.

Regulatory Status

Selank’s regulatory position is worth stating plainly:

• Selank is not FDA approved for any indication, and no Selank drug product has been approved in the United States or the European Union.
• Selank is registered as a prescription anxiolytic in Russia, where it has been studied clinically for generalized anxiety disorder and neurasthenia. Registration in Russia is not FDA approval and does not establish safety or efficacy to international regulatory standards.
• The Russian clinical literature on Selank was conducted under domestic regulatory frameworks and trial designs that differ from multinational standards — a fact researchers should weigh when evaluating the evidence.

What Does the Research Say?

The Selank literature provides a basis for continued research into peptide-mediated anxiolytic mechanisms — particularly the unusual combination of reported anxiolytic activity without benzodiazepine-like sedation, and the enkephalin-stabilization and GABAergic-gene-modulation findings that give that profile a proposed molecular basis.

However, the evidence limitations are significant and should be understood clearly:

First, a large share of the Selank literature is published in Russian-language journals, much of it not indexed in the Western databases most researchers search. The literature is real and decades deep, but difficult to systematically review — an evidence-accessibility problem shared with Semax.

Second, the human research — the medazepam and phenazepam comparisons, the anxiety-asthenic immunomodulation studies — was conducted within Russia’s domestic framework. Without multinational, double-blind, placebo-controlled trials published in international journals, the human evidence does not meet the standard applied to Western drug evaluation, regardless of the compound’s registered status in Russia.

Third, the most exportable mechanistic findings (GABAergic gene expression, BDNF regulation) are preclinical and come from a small number of research groups at the same institute. The distance between “modulates GABAergic gene expression in rat brain” and any human outcome remains unbridged by international-standard evidence.

An anxiolytic registered in one regulatory system is not the same as an internationally validated one, and enthusiasm around Selank should be tempered by the geography and methodology of its evidence base.

Frequently Asked Questions

What is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the natural immunoregulatory tetrapeptide tuftsin, with a Pro-Gly-Pro stability tail. Developed in Russia, it has been researched primarily for anxiolytic, GABAergic, neurotrophic, and immunomodulatory biology.

Is Selank FDA approved?

No. Selank is not FDA approved for any indication. It is registered as a prescription anxiolytic in Russia, where it has been studied for generalized anxiety disorder and neurasthenia — Russian registration is not FDA approval.

What does the research show?

Russian studies reported anxiolytic effects comparable to certain benzodiazepines (medazepam, phenazepam) without the associated sedation, alongside antiasthenic properties. Preclinical research reported GABAergic gene modulation, enkephalin-enzyme inhibition, and BDNF expression changes in rat brain. All human data comes from Russia’s domestic clinical framework, not international trials.

How is Selank different from Semax?

Both are Russian-developed heptapeptides from the same research program with the same Pro-Gly-Pro tail, but they differ in origin and focus: Semax is an ACTH(4-7) analog studied mainly for neurotrophic signaling and neuroprotection, while Selank is a tuftsin analog studied mainly for anxiolytic and immunomodulatory properties.

Has Selank been tested in humans?

Yes — in Russian clinical research, consistent with its registered status there. Published studies compared Selank against medazepam and phenazepam in anxiety disorders and investigated immunomodulatory effects in anxiety-asthenic patients. These studies were published primarily in Russian journals under domestic frameworks, not as multinational trials in international journals.

The Bottom Line

Selank is a distinctive case in peptide research — a tuftsin-derived heptapeptide with a reported anxiolytic profile lacking benzodiazepine-style sedation, human comparison studies against established anxiolytics, and proposed mechanisms spanning GABAergic gene modulation, enkephalin stabilization, and BDNF expression — within a literature that is deep but geographically concentrated and distant from international trial standards.

The enkephalin and GABAergic-gene findings give Selank genuine mechanistic interest beyond its anxiolytic reputation. But the evidence geography — Russian-language journals, domestic clinical frameworks, preclinical mechanism work — means the compound’s profile should be read with unusual source-critical care.

For researchers interested in non-sedating anxiolytic mechanisms, neuroimmune peptide biology, and the distinctive Russian peptide-pharmacology tradition, Selank remains an important and carefully-qualified area of ongoing research.

Explore Selank

Learn more about Selank and explore our research-focused Selank peptide at Vonox Labs: Selank

Research. Test. Learn.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. https://pubmed.ncbi.nlm.nih.gov/18841804/ (Reported Selank-induced regulation of BDNF mRNA and protein levels in rat hippocampus.)
• Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. https://pubmed.ncbi.nlm.nih.gov/26924987/ (Open-access transcriptomic study reporting Selank-associated changes in GABAergic gene expression in rat brain.)
• Sokolov OY, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bull Exp Biol Med. 2002;133(2):133-135. https://pubmed.ncbi.nlm.nih.gov/12432865/ (Reported anxiolytic effects in BALB/c mice associated with inhibition of enkephalin-degrading enzymes.)
• Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/ (Russian clinical comparison of Selank vs. medazepam in generalized anxiety disorder and neurasthenia; reported comparable anxiolytic efficacy with additional antiasthenic properties.)
• Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. https://pubmed.ncbi.nlm.nih.gov/25176261/ (Russian clinical comparison of Selank vs. phenazepam; domestic trial framework.)
• Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. https://pubmed.ncbi.nlm.nih.gov/18577961/ (Investigated Selank’s immunomodulatory effects alongside anxiolytic activity in patients with anxiety-asthenic disorders.)
• Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II, Zuikov AV. Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. Bull Exp Biol Med. 2007;144(5):689-691. https://pubmed.ncbi.nlm.nih.gov/18683497/ (Reported normalization of cognitive processes in rats with early-life catecholamine-system damage.)
• Sollertinskaya TN, Shorokhov MV, Kozlovskaya MM, Kozlovskii II, Sudakov KV. [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]. Zh Evol Biokhim Fiziol. 2008;44(3):284-290. https://pubmed.ncbi.nlm.nih.gov/18727417/ (Reported compensatory and memory-protective effects of Selank in a non-human primate model; English translation: J Evol Biochem Physiol. 2008;44:332-340.)
• Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. https://pubmed.ncbi.nlm.nih.gov/28280289/ (Open-access study on Selank in a chronic-stress rat model, including a review of Selank’s researched mechanisms and history.)